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Introduction: Chronic hepatitis B (CHB) is a prevalent disease associated with high   morbidity, 
mortality, and impact on health care costs. Antiviral therapy is aimed at reducing hepatitis B 
virus replication in order to limit progressive liver disease and improve the natural history of 
the disease. This study estimates the cost-effectiveness of lamivudine, adefovir, telbivudine, 
entecavir, tenofovir, and pegylated interferon in patients with CHB.
Methods: A Markov model was developed to evaluate the costs and benefits of antivirals in 
a cohort of patients with CHB (hepatitis B e antigen [HBeAg]-positive and HBeAg-negative) 
and cirrhosis over a period of 10 years. Different rescue therapies were considered, according 
to current guidelines. Data on efficacy and changes in quality of life were derived from clinical 
trials and epidemiological Italian data. Direct costs were assessed from the perspective of the 
Italian National Health Service.
Results: Tenofovir was associated with lower costs and higher efficacy compared with 
entecavir, telbivudine, and adefovir, as shown by their incremental cost-effectiveness ratios 
(ICER) per quality-adjusted life-year (QALY) gained: tenofovir €30,959, entecavir €45,971, 
telbivudine €62,051, and adefovir €82,824. Even following 1 year of pegylated interferon 
therapy, tenofovir had a more favourable ICER per QALY gained compared with the other 
rescue options. The analysis of patients with cirrhosis confirms the results obtained with the 
CHB cohort though with higher ICERs. Sensitivity analyses on the main variables confirm the 
results of the base case scenario.
Conclusion: Within the Italian health care system, in patients with CHB, tenofovir is a 
  cost-effective strategy compared with other available therapies. Public health care authorities 
would benefit from mathematical models designed to estimate the future burden of CHB   infection 
together with the impact of treatment and drug resistance.
Keywords: chronic hepatitis B, Markov model, cost-effectiveness, lamivudine, adefovir, 
telbivudine, entecavir, tenofovir, pegylated interferon
Introduction
Chronic infection with hepatitis B virus (HBV) is a common cause of death associated 
with liver failure, cirrhosis, and hepatocellular carcinoma (HCC).1 Despite the 
  implementation of vaccination programs in various countries, the condition is still 
widespread, affecting 350 million to 400 million people worldwide.2
Morbidity and mortality in chronic hepatitis B (CHB) are related to   persistence of 
viral replication and evolution to cirrhosis or HCC.1 Treatment for CHB is therefore 
aimed at suppressing HBV replication to prevent progression of the disease. The current 
therapeutic options available in Italy and Europe include interferon α, conventional ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
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or pegylated, and nucleoside/nucleotide analogs (NUCs). 
  Interferon is administered subcutaneously, and its main 
advantage is the absence of resistance. Nonetheless, its use 
is limited by frequent side effects and the fact that it is 
  considered a moderate antiviral agent.1 NUCs vary greatly in 
terms of efficacy, induced viral resistance, and tolerance. 
Lamivudine and adefovir are early-generation oral agents 
whose main disadvantage is the high viral resistance they 
engender.3 Telbivudine is a potent inhibitor of HBV but 
with a high rate of viral resistance.2 Conversely, the latest-
generation NUCs entecavir and tenofovir are both potent 
HBV inhibitors with an optimal resistance profile.4–6
The relevant role of entecavir and tenofovir has recently 
been highlighted by the European Association for the 
Study of the Liver (EASL), whose guidelines recommend 
  pegylated interferon, entecavir, or tenofovir as first-line 
treatment for both hepatitis B e antigen (HBeAg)-positive 
and HBeAg-negative patients.1
Considering the complexity of the disease, the EASL ’s 
  recommendations are invaluable in assisting physicians in 
selecting the most favourable therapies. However, because 
CHB is a prolonged illness, the treatment of which may 
continue for many years, the need for drugs with potent 
antiviral   activity, proven long-term safety, and a low rate of 
HBV antiviral resistance1 should also be evaluated in terms 
of lifetime costs.
In a global context of limited health care resources, 
pharmacoeconomic considerations are a central factor to 
help policy makers make the most appropriate decisions on 
resource allocation. We therefore performed an economic 
analysis to estimate the cost-effectiveness of the treatments 
licensed in Italy for managing HBV infection in patients with 
chronic hepatitis and cirrhosis. We also estimated the impact 
of the disease on the quality of life of patients.
Patients and method
Model overview
We built a Markov model and evaluated the clinical and 
economic outcomes of a hypothetical cohort of 100   subjects 
(aged $18 years) with chronic HBV (92.70%) or   cirrhosis 
(7.30%) over a 10-year horizon. The proportions of 
the two subpopulations were obtained from a study by 
  Giannini et al.7
To mirror the case mix in clinical practice in Italy, 
we assumed that 20% of them were HBeAg-positive and 
80% were HBeAg-negative.8 The terms “HBeAg-positive” 
and “HBeAg-negative” define two categories of the CHB 
status, the first typically represents the early phase of 
chronic HBV infection, whereas the second represents a 
later phase.1
In the model, the individual’s possible prognosis is 
divided into distinct health states. Costs and benefits are 
assigned to each health state and the movement of an individ-
ual between these health states over a given amount of time 
(each cycle of 1 year) is defined by transition probabilities. 
The costs and benefits of comparative treatments are then 
estimated according to the time spent in each state.
Because  HBeAg-negative  and  HBeAg-positive 
  populations present a different clinical course, prognosis, 
and response to therapy, separate transition probabilities 
were assigned to each group.
The model, which is represented in Figure 1, was 
  structured with the following assumptions:
•	 On entering the model, previously untreated subjects 
start to receive one of the following competing options: 
i) no treatment, ii) tenofovir monotherapy, iii)   lamivudine 
monotherapy, iv) adefovir monotherapy, v) entecavir mono-
therapy, vi) telbivudine monotherapy, and vii)   pegylated 
interferon monotherapy.
Chronic hepatitis B Spontaneous resolution Normal life expectancy
Compensated cirrhosis Decompensated cirrhosis Liver transplantation Transplanted
Hepatocellular carcinoma
Death
Figure 1 Structure of the Markov model for chronic hepatitis B.ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
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•	 At the end of each cycle (1 year), the subjects with 
virologic response remain in the same state, whereas 
nonresponders move to the subsequent health states.
•	 Subjects who do not respond or who develop resistance 
to treatment receive a rescue therapy, ie, a second drug, 
according to the following scheme:
Initial treatment  Rescue therapy
tenofovir  →  add-on entecavir
lamivudine  →  add-on tenofovir
adefovir  →  add-on entecavir
entecavir  →  add-on tenofovir
telbivudine  →  add-on tenofovir
pegylated interferon  →    switch  to  entecavir  or 
tenofovir
•	 In case of resistance, subjects with CHB remain in 
the state “chronic hepatitis B”, whereas subjects with 
  cirrhosis move to the subsequent states.
•	 Subjects who achieve HBeAg seroconversion discontinue 
therapy 12 months later; patients who achieve hepatitis 
B surface antigen (HBsAg) seroconversion discontinue 
therapy definitely.
According to the EASL guidelines, virologic response 
is achieved when HBV DNA level is reduced below the 
lower limit of detection of real-time polymerase chain 
reaction assays (10–15 IU/mL), resulting in biochemical 
remission, histological improvement, and prevention of 
complications.1
Seroconversion from HBeAg to anti-HBe antibodies 
with normal transaminases, leading to the “inactive HBV 
carrier state”, represents the immunological control of the 
infection and reflects a favorable long-term outcome with a 
very low risk of cirrhosis or HCC in most subjects.1 HBsAg 
loss or seroconversion is more rarely achieved and represents 
serologic recovery.2 Both these possibilities were considered 
in the model.
A discount rate was applied to costs and utilities (range 
0%–3%). Modeling was undertaken using Microsoft Excel 
2003 (Microsoft Corporation, Redmond, Washington, USA).
Transition probabilities
Subjects who received no treatment followed the natural 
history of CHB according to their HBeAg status. The 
  corresponding transition probabilities were derived from 
a study by Idris et al.9 Subjects who received one of the 
six available therapeutic options progressed to virologic 
response, nonresponse, and resistance according to the drug 
they were given. The transition probabilities were derived 
from literature data (Tables 1 and 2). When data were not 
available, it was assumed that the response remained constant 
at the last observed value by applying the last value carried 
forward technique.
Outcomes
To evaluate cost-effectiveness, the incremental cost-
  effectiveness ratio (ICER) was used. When the value of 
a new therapeutic option needs to be assessed, the ICER 
provides the additional resources that have to be used 
to achieve the additional benefit. ICER is the difference 
in cost (∆C) divided by the difference in effect (∆E) 
between two alternatives. In this analysis, the direct costs 
Table 1 input data of the base case scenario
Variable Value Reference
HBeAg-positive 20.00% 8
Chronic infection 92.70% 7
Cirrhosis 7.30%
Transition probabilities Annual rates of events according to HBeAg
Positive Negative
Chronic hepatitis B Spontaneous resolution 6.90% 1.60% 9
Compensated cirrhosis 3.00% 4.60%
Hepatocellular carcinoma 1.50% 1.50%
Compensated cirrhosis Decompensated cirrhosis 7.30% 7.30% 9
Hepatocellular carcinoma 3.40% 3.40%
Death 4.90% 4.90%
Decompensated cirrhosis Liver transplantation 21.00% 21.00% 9
Death 19.00% 19.00%
Hepatocellular carcinoma Liver transplantation 25.00% 25.00% 9
Death 43.30% 43.30%
Liver transplantation Death 6.90% 6.90% 9
Abbreviation: HBeAg, hepatitis B e antigen.ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
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Table 2 virologic response, HBv resistance, and seroconversion rates for each antiviral drug for both HBeAg-positive and -negative 
patients
List of variable
 
Value Reference 
Years
1 2 3 4 5
Undetectable HBV DNA
HBeAg-positive 
Tenofovir  76.00% 78.00% 72.00% 5,10,11
Lamivudine 36.00% 12,13
Adefovir 21.00% 40.00% 48.00% 13,14
Entecavir1 67.00% 80.00% 82.00% 12,13
Telbivudine 60.00% 56.00% 15,16
Peginterferon 25.00% 1,13
HBeAg-negative
Tenofovir  93.00% 91.00% 88.00% 5,17,18
Lamivudine 89.00% 63.00% 48.00% 39.00% 19
Adefovir 72.00% 80.00% 77.00% 73.00% 67.00% 20
Entecavira 90.00% 94.00% 93.00% 91.00% 95.00% 13,21–24
Telbivudine 88.00% 82.00% 84.00% 16,25
Peginterferon 63.00%       1,13
Development of resistance
HBeAg-positive 
Tenofovir  0.00% 0.00% 0.00% 1,11,26
Lamivudine 23.00% 46.00% 55.00% 71.00% 65.00% 27
Adefovir 20.00% 28
Entecavir 0.20% 0.50% 1.20% 1.20% 1.20% 29
Telbivudine 5.00% 25.10% 15,30
Peginterferon na
HBeAg-negative 
Tenofovir  0.00% 0.00% 0.00% 1,18,26
Lamivudine 20.00% 44.00% 60.00% 19,31
Adefovir 0.00% 3.00% 11.00% 18.00% 29.00% 20
Entecavir
Telbivudine 2.20% 11.00% 15,30
Peginterferon na         
HBsAg clearance/seroconversion
HBeAg-positive 
Tenofovir  3.00% 6.00% 8.00% 5,10,11
Lamivudine 0.00%
Adefovir 0.00%
Entecavir 2.00% 4
Telbivudine 0.00%
Peginterferon 4.00% 6.00% 8.00% 32,33
HBeAg-negative 
Tenofovir  0.00% 0.00% 0.00% 5,17,18
Lamivudine 0.00% 0.00% 0.00%
Adefovir 0.00% 0.00% 0.00%
Entecavir 0.00%
Telbivudine 0.00%
Peginterferon 3.00% 6.00% 8.00%     34,35
HBeAg seroconversion
HBeAg-positive 
Tenofovir  21.00% 26.00% 26.00% 1,5,10,11,36
Lamivudine 22.00% 22.50% 1,15,36
Adefovir 12.00% 29.00% 43.00% 1,36–38
Entecavir 21.00% 24.00% 16.00% 1,36,38–40
Telbivudine 23.00% 30.00% 1,36,41
Peginterferon 30.00% 41.00% 1,36,42
Note: aData beyond 1 year need to be interpreted with caution due to regimen intensification, including doubling of dose.
Abbreviations: HBeAg, hepatitis B e antigen; HBv, hepatitis B virus.ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
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and effectiveness of each drug were compared with the 
direct costs and effectiveness of the disease natural history 
(absence of treatment).
  (Costdrug − Costabsence of treatment)
ICER = 
  (Effectivenessdrug − Effectivenessabsence of treatment)
Utilities
The analysis conducted is a cost–utility analysis, ie, an 
  economic evaluation that estimates the cost per quality-
adjusted life-year (QALY) gained from undertaking one 
intervention instead of another.43 The QALY is a potential 
measure of health and is obtained by multiplying the   duration 
of a health state (in years) by a factor representing the 
  quality (“utility”) of that health state. A QALY value of 1 is 
  equivalent to a year of “perfect health”, whereas a value of 
zero corresponds to “death”. Utilities were considered for the 
following states: virologic response (1.000), inactive HBV 
carrier (0.960), CHB (0.910), compensated cirrhosis (0.800), 
decompensated cirrhosis (0.600), HCC (0.730), and liver 
transplantation (0.860).44–46 These values were calculated 
using the Health Utility Index (HUI).47
Costs
Only direct health care costs (ie, health service costs) 
were considered in the analysis, which were calculated 
from the Italian National Health Service’s perspective. 
These costs pertained to annual costs per person and 
included expenditures related to the diagnosis of the 
  disease,   laboratory testing, drugs, follow-up, and disease 
  complication costs. In the case of tenofovir, costs also 
included periodic   monitoring of renal functioning, which 
was performed monthly during the first year and every 
3 months for the following years (Table 3).
Results
The model was built using epidemiological data of CHB 
prevalence in Italy. Our results show that the mean annual 
cost per patient with CHB or cirrhosis receiving antiviral 
therapy was between €2573 and €7639 compared with sub-
jects who received no treatment. The ICER per QALY gained 
for a) tenofovir monotherapy, b) pegylated interferon (first 
year) followed by tenofovir, c) pegylated interferon (first 
year) followed by entecavir, d) lamivudine with early add-on 
tenofovir, and e) entecavir monotherapy were all favorable 
at a threshold of €50,000 per QALY compared with the 
natural history of the disease and varied between €30,959 
and €45,971 (Table 4). Conversely, telbivudine and adefovir 
did not have a favourable ICER compared with the natural 
history of the disease, as their range was between €62,051 
and €82,824 per QALY gained (Table 4). Of note, because of 
the optimal combination of cost and effectiveness, tenofovir 
was the strategy with the best ICER.
Table 3 Cost data: average cost of different stages of the disease 
(€, year 2009 values) and annual drug costs
Antiviral Annual cost (€) Reference
Tenofovir 3062.35 48
Lamivudine 1153.40 48
Adefovir 4595.35 48
Entecavir 4595.35 48
Telbivudine 4595.35 48
Peginterferon 8356.55 48
Disease state Annual cost (€)a
Chronic hepatitis B 1977.02 49
Compensated cirrhosis 3384.56 49
Decompensated cirrhosis 3384.56 49
Hepatocellular carcinoma 6808.71 49
Liver transplantation 82867.40 49
Follow-up post-transplantation 6358.04 50
Monitoring for nephrotoxic effects 23.50 51 
52
Note: aCosts of drugs are excluded.
Table 4 Results: costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratio (iCER) of the base case scenario 
(10-year horizon)
Treatment  Mean annual  
cost per  
patient (€)
Mean annual 
QALY per  
patient
Mean cost per 
QALY (€)
Delta cost (€) Delta 
QALY
ICER per 
QALY (€) 
12 months
a b a/b ∆a ∆b ∆a/∆b
Natural history of disease 2572.84 0.815 3158.74
Tenofovir 5116.00 0.896 5711.00 2543.00 0.081 31,291
Peginterferon (first year) →	tenofovir 5276.00 0.897 5883.00 2703.00 0.082 32,863
Peginterferon (first year) →	entecavir 6206.00 0.897 6922.00 3633.00 0.082 44,243
Lamivudine (→	add-on tenofovir) 4737.00 0.862 5495.00 2164.00 0.048 45,513
Entecavir 6302.00 0.895 7043.00 3729.00 0.080 46,498
Telbivudine 6970.00 0.885 7878.00 4397.00 0.070 62,642
Adefovir 7679.00 0.876 8769.00 5106.00 0.061 83,475ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
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By estimating the cost of the different strategies at 5 
and 10 years, we showed that tenofovir alone or following 
pegylated interferon in a group of HBeAg-positive patients 
contributed to reducing the costs of disease management 
over time.
In our simulation, HBeAg-positive subjects showed more 
favorable ICERs compared with HBeAg-negative subjects, 
whereas, as assessed in the sensitivity analyses, treatment of 
subjects with cirrhosis resulted in higher ICERs, which often 
exceeded the international threshold of cost-effectiveness 
of €25,000–35,000 (about £20,000–30,000) indicated, for 
example, by the National Institute for Health and Clinical 
Excellence (NICE).53
To test the robustness of our evaluations, sensitivity 
analyses were carried out by varying parameters such as 
the proportion of HBeAg-positive and HBeAg-negative 
subjects, the proportion of subjects with cirrhosis, the cost 
of tenofovir and entecavir, and the overall cost of patient 
management. Other sensitivity analyses were carried out 
for the inclusion of bone mineral densitometry for subjects 
on tenofovir and discounting for costs and QALYs. In all 
cases, the results of the base case scenario were confirmed 
(Table 5 and Figure 4).
Discussion
Chronic HBV infection is a prevalent disease, the management 
of which is associated with high costs due to treating 
  complications, antiviral drug therapy, and monitoring of 
HBV drug resistance.9 Current guidelines have provided 
physicians with clear recommendations on how to select 
the most effective treatments for each patient.1 However, 
their indications have failed to include pharmacoeconomics 
considerations to address the financial burden of CHB and 
its consequences on the limited health care budgets of many 
countries.
To contribute to a better understanding of the impact of 
managing subjects with CHB in Italy, we have developed 
a cost-effectiveness analysis on the six treatments that are 
currently available. Our results have shown that tenofovir is 
the most cost-effective oral antiviral compared with the other 
agents for HBeAg-positive and HBeAg-negative subjects 
and for patients with cirrhosis. In the case of drug failure, the 
use of tenofovir and entecavir as rescue therapies has a more 
favorable ICER than the use of adefovir and lamivudine. 
  Furthermore, tenofovir assessment has included costs for 
renal monitoring and bone mineral densitometry, which were 
not considered in the most recent published studies.6,54,55
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The ICER per QALY gained was below the threshold 
of €23,000–34,000 (about £20,000–30,000) set by NICE 
only in the case of tenofovir as first-line treatment or as 
rescue therapy following pegylated interferon. In all other 
cases, ICER per QALY gained exceeded NICE’s threshold. 
Though no officially established threshold is available for 
Italy, it is worth noting that recent guidelines by the Italian 
Health Economics Association (AIES)56 recommend that a 
threshold of €25,000–40,000 be adopted. Other acceptable 
references of cost-effectiveness for the Italian context are 
€36,500 and €60,000 and have been calculated by two 
  different authors.57,58
Our results are in line with other recent pharmacoeconom-
ics analyses, in particular with the study of Buti et al54 and 
with the more recent cost–utility analysis of Dakin et al.55 
Unlike these two studies, though, which assessed only the 
cost-  effectiveness of NUCs, we were also able to model the 
treatment with pegylated interferon and show that the strategy 
of using pegylated interferon (first year) followed by tenofovir 
may represent a good cost-effectiveness solution for HBeAg-
  positive subjects, although this approach is not as cost-  effective 
as starting with tenofovir for HBeAg-  negative   subjects. 
  Conversely, peginterferon usage as first-line therapy in 
  cirrhotic patients seems to not be cost-effective.   Furthermore, 
health care authorities would benefit from   treating patients 
before they develop cirrhosis, as shown by lower ICERs. 
In this way, as all available treatment strategies for CHB were 
  evaluated, the model can be employed to make projections of 
health care spending within the National Health Service.
Based on all these findings, it appears that the “economic” 
profile of tenofovir is in line with its optimal clinical profile, 
as outlined in the EASL ’s guidelines, where, together with 
pegylated interferon and entecavir, tenofovir is recommended 
as first-line treatment for both HBeAg-positive and HBeAg-
negative subjects with CHB.1
The study has a few limitations, the most important of 
which concerns the quality of data entered into the model. 
Parameters such as efficacy, for example, are based on studies 
with a limited timeframe and hence may be inadequate for 
modeling the treatment of a chronic disease for a longer 
time. Another important limitation is with regard to the 
  assumptions on which the analysis is based, which may be 
necessary to simplify the model or in cases of incomplete 
data. Specifically, this was with regard to the transition 
probabilities, which were lacking in some cases and thus 
assumed to remain constant over time, and the utilities, which 
were derived from different literature sources and considered 
to be acceptable for an Italian population.
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Figure 4 Results of one-way sensitivity analyses.
Despite these drawbacks, which are typical of most 
model-based economic evaluations, our study contributes 
to confirming the cost-effectiveness of some drugs, and in 
particular of tenofovir, also in the Italian context.
To conclude, it is worth noting that the developed model 
is a dynamic instrument that can be adapted to various 
health care settings, in that it can be run using different input 
data (ie, efficacy, cost, and epidemiological). By allowing 
simulations of different scenarios, it represents an invaluable 
tool for policy makers and health care professionals to make 
short- and long-term cost projections and thus evaluate their 
impact on the available budgets.
Acknowledgements
We thank Sara A Ratti for preparing the first draft of this 
paper.ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
45
Cost-effectiveness analysis of therapies for chronic hepatitis B
Declaration
The study was financially supported by Gilead Sciences Srl, 
Milan, Italy.
References
  1.  European Association for the Study of the Liver. EASL clinical practice 
guidelines: management of chronic hepatitis B. J Hepatol. 2009;50(2): 
227–242.
  2.  Dienstag JL. Hepatitis B virus infection. N Engl J Med. 2008;359(14): 
1486–1500.
  3.  Carey I, Harrison PM. Monotherapy versus combination therapy for 
the treatment of chronic hepatitis B. Expert Opin Investig Drugs. 2009; 
18(11):1655–1666.
  4.  Chang TT, Gish RG, de Man R, et al; BEHoLD AI463022 Study Group. 
A comparison of entecavir and lamivudine for HBeAg-positive chronic 
hepatitis B. N Engl J Med. 2006;354(10):1001–1010.
  5.  Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate 
versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008; 
359(23):2442–2455.
  6.  Woo G, Tomlinson G, Nishikawa Y, et al. Tenofovir and entecavir are 
the most effective antiviral agents for chronic hepatitis B: a systematic 
review and Bayesian meta-analyses. Gastroenterology. 2010 [Epub 
ahead of print].
  7.  Giannini EG, Torre F, Basso M, et al; Ligurian Hepatitis B Virus Study 
Group. A significant proportion of patients with chronic hepatitis B 
who are candidates for antiviral treatment are untreated: a region-wide 
survey in Italy. J Clin Gastroenterol. 2009;43(10):1001–1007.
  8.  Gaeta GB, Stornaiuolo G, Precone DF, et al. Epidemiological and 
clinical burden of chronic hepatitis B virus/hepatitis C virus infection. 
A multicenter Italian study. J Hepatol. 2003;39(6):1036–1041.
  9.  Idris BI, Brosa M, Richardus JH, et al. Estimating the future health 
burden of chronic hepatitis B and the impact of therapy in Spain. Eur 
J Gastroenterol Hepatol. 2008;20(4):320–326.
  10.  Heathcote JE, Gane EJ, de Man A, et al. Two year tenofovir disoproxil 
fumarate (TDF) treatment and adenofovir dipivoxil (ADV) switch 
data in HbeAg-positive patients with chronic hepatitis B (Study 103), 
preliminary analysis [Abstract]. Hepatology. 2008;48 Suppl 4:309A.
  11.  Heathcote JE, Gane EJ, de Man A, et al. Three years of tenofovir 
disoproxil (TDF) treatment in HbeAg-positive patients (HBeAg+) 
with chronic hepatitis B (Study 103), preliminary analysis [Abstract]. 
Hepatology. 2009;50 Suppl 4:533A.
  12.  Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and 
lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 
2006;354(10):1001–1010.
  13.  Lai CL, Yuen MF. Chronic hepatitis B: new goals, new treatment.   
N Engl J Med. 2008;359(23):2488–2491.
  14.  Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the 
treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl 
J Med. 2003;348(9):808–816.
  15.  Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients 
with chronic hepatitis B. N Engl J Med. 2007;357(25):2576–2588.
  16.  Lai CL, Gane E, Hsu CW, et al. Two-year results from the globe trial 
in patients with hepatitis B: greater clinical and antiviral efficacy for 
telbivudine (LDT) vs lamivudine [Abstract]. Hepatology. 2006;44 
Suppl 1:222A.
  17.  Marcellin P, Buti M, Krastev Z, et al. Two year tenofovir   disoproxil 
fumarate (TDF) treatment and adenofovir dipivoxil (ADV) switch 
data in HbeAg-negative patients with chronic hepatitis B (Study 
102), preliminary analysis [Abstract]. Hepatology. 2008;48   
Suppl 4:370A.
  18.  Marcellin P, Buti M, Krastev Z, et al. Three years of tenofovir disoproxil 
(TDF) treatment in HbeAg-positive patients (HBeAg+) with chronic 
hepatitis B (Study 103), preliminary analysis [Abstract]. Hepatology. 
2009;50 Suppl 4:532A.
  19.  Di Marco V , Marzano A, Lampertico P, et al. Italian Association for 
the Study of the Liver (AISF) Lamivudine Study Group, Italy. Clinical 
  outcome of HBeAg-negative chronic hepatitis B in relation to virological 
response to lamivudine. Hepatology. 2004;40(4):883–891.
  20.  Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir 
  Dipivoxil 438 Study Group. Long-term therapy with adefovir 
dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. 
  Gastroenterology. 2006;131(6):1743–1751.
  21.  Senturk H, Lurie Y, Gadano A, et al. ETV re-treatment of nucleoside-
naive HBeAg(−) [Abstract]. J Hepatol. 2007;46 Suppl 1:S197.
  22.  Shouval D, Lai CL, Chang TT, et al. Three years of entecavir 
(ETV) re-treatment of HBeAg(−) ETV patients who previously 
  discontinued ETV treatment: results from study ETV-901. Hepatology. 
2008;48 Suppl 4:722A.
  23.  Lai CL, Shouval D, Lok AS, et al; BEHoLD AI463027 Study Group. 
Entecavir versus lamivudine for patients with HBeAg-negative chronic 
hepatitis B. N Engl J Med. 2006;354(10):1011–1020. Erratum in:   
N Engl J Med. 2006;354(17):1863.
  24.  Shouval D, Akarca US, Hatzis G, et al. Continued virologic and 
biochemical improvement through 96 weeks of entecavir treatment in 
HBeAg(−) chronic hepatitis B patients (study ETV-027). J Hepatol. 
2006;44 Suppl 2:S21–S22.
  25.  Wang Y, Thongsawat S, Gane EJ, et al. Efficacy and safety   outcomes 
after 4 years of telbivudine treatment in patients with chronic   
hepatitis B (CHB). Hepatology. 2009;50 Suppl 4:533A.
  26.  Snow-Lampart A, Chappell BJ, Curtis M, et al. HBeAg+ and HBeAg− 
hepatitis B patients treated with tenofovir df showed no relationship 
between virologic breakthrough and emergence of genotypic changes 
in HBV polymerase. Hepatology. 2009;50 Suppl 4:523A.
  27.  Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine 
treatment in patients with chronic hepatitis B. Gastroenterology. 2003; 
125(6):1714–1722.
  28.  Marcellin P, Chang TT, Lim SG, et al. Long-term efficacy and safety 
of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive 
chronic hepatitis B. Hepatology. 2008;48(3):750–758.
  29.  Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows 
hepatitis B virus resistance to entecavir in nucleoside-naïve patients is 
rare through 5 years of therapy. Hepatology. 2009;49(5):1503–1514.
  30.  Liaw YF, Gane E, Leung N, et al. GLOBE Study Group. 2-year GLOBE 
trial results: telbivudine is superior to lamivudine in patients with 
chronic hepatitis B. Gastroenterology. 2009;136(2):486–495.
  31.  Fontana RJ. Hepatitis B: a “GLOBAL” health challenge. Gastroenterology. 
2009;136(2):389–392.
  32.  Buster EH, Flink HJ, Cakaloglu Y, et al. Sustained HBeAg and HBsAg 
loss after long-term follow-up of HBeAg-positive patients treated with 
peginterferon alpha-2b. Gastroenterology. 2008;135(2):459–467.
  33.  Janssen HL, van Zonneveld M, Senturk H, et al. HBV 99-01 Study Group; 
Rotterdam Foundation for Liver Research. Pegylated interferon alfa-2b 
alone or in combination with lamivudine for HBeAg-positive chronic 
hepatitis B: a randomised trial. Lancet. 2005;365(9454):123–129.
  34.  Marcellin P, Lau GK, Bonino F, et al. Peginterferon Alfa-2a HBeAg-
Negative Chronic Hepatitis B Study Group. Peginterferon alfa-2a 
alone, lamivudine alone, and the two in combination in patients with 
HBeAg-negative chronic hepatitis B. N Engl J Med. 2004;351(12): 
1206–1217.
  35.  Marcellin P, Bonino F, Lau GK, et al. Peginterferon alfa-2a in HBeAg-
negative Chronic Hepatitis B Study Group. Sustained response of hepatitis 
B e antigen-negative patients 3 years after treatment with peginterferon 
alpha-2a. Gastroenterology. 2009;136(7):2169–2179:e1–e4.
  36.  Lau GK. Current treatments for patients with HBeAg-positive 
chronic hepatitis B virus infection: a comparison focusing on HBeAg 
seroconversion. Liver Int. 2010;30(4):512–520.
  37.  Marcellin P, Chang TT, Lim S, et al. Long term efficacy and safety of 
adefovir dipivoxil (ADV) 10 mg in HBeAg+ chronic hepatitis B (CHB) 
patients increasing serologic, virologic and biochemical response over 
time. Hepatology. 2004;40(1) Suppl 4:655A.ClinicoEconomics and Outcomes Research
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/clinicoeconomics-and-outcomes-research-journal
ClinicoEconomics & Outcomes Research is an international, peer-
reviewed open-access journal focusing on Health Technology Assess-
ment, Pharmacoeconomics and Outcomes Research in the areas of 
diagnosis, medical devices, and clinical, surgical and pharmacological 
intervention. The economic impact of health policy and health systems 
organization also constitute important areas of coverage. The manu-
script management system is completely online and includes a very 
quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
46
Colombo et al
  38.  Leung N, Peng CY, Sollano J, et al. Entecavir (ETV) results in higher 
HBV DNA reduction versus adefovir (ADV) in antiviralnaive HBeAg+ 
adults with high HBVDNA: Week 96 results (E.A.R.L.Y. study).   
J Hepatol. 2008;48:S373–S374.
  39.  Yao G, Chen CW, Lu WL, et al. Virologic, serologic, and biochemical 
outcomes through 2 years of treatment with entecavir and lamivu-
dine in nucleoside-naive Chinese patients with chronic hepatitis B:   
a randomized, multicenter study. Hepatol Int. 2008;2:486–493.
  40.  Han S, Chang T-T, Chao YC, et al. Four-year entecavir treatment in 
nucleosidenaïve HBeAg(+) patients: results from studies ETV-022   
And -901. Hepatology. 2007;46(4) Suppl 1:654A.
  41.  Hou J, Yin YK, Xu D, et al. Telbivudine versus lamivudine in Chinese 
patients with chronic hepatitis B: results at 1 year of a randomized, 
double-blind trial. Hepatology. 2008;47:447–454.
  42.  Piratvisuth T, Lau G, Chao YC, et al. Sustained response to peginterferon 
alfa-2a (40 kD) with or without lamivudine in Asian patients with 
HBeAg-positive and HBeAg-negative chronic hepatitis B. Hepatol 
Int. 2008;2(1):102–110.
  43.  Drummond MF, Schulpher MJ, Torrance GW, et al. Methods for the 
Economic Evaluation of Health Care Programmes. 3rd ed. Oxford: 
Oxford University Press; 2005.
  44.  Enriquez AD, Campbell MS, Reddy KR. Cost-effectiveness of 
  suppressing hepatitis B virus DNA in immune tolerant patients to 
prevent hepatocellular carcinoma and cirrhosis. Aliment Pharmacol 
Ther. 2007;26(3):383–391.
  45.  Sullivan SD, Craxi A, Alberti A, et al. Rapporto costo efficacia della 
terapia peginterferone alfa-2a+ribavirina in confronto a interferone 
alfa-2b+ribavirina in pazienti affetti da epatite cronica di tipo C 
  precedentemente non trattati. PharmacoEconomics. 2004;6:105–114.
  46.  Kanwal F, Gralnek IM, Martin P, et al. Treatment alternatives for chronic 
hepatitis B virus infection: a cost-effectiveness analysis. Ann Intern 
Med. 2005;142(10):821–831.
  47.  Chapman RH, Stone PW, Sandberg EA, et al. A comprehensive league 
table of cost-utility ratios and a sub-table of “panel-worthy” studies. 
Med Decis Making. 2000;20(4):451–467.
  48.  Health Ministry. National Tariff Nomenclature. Nomenclatore delle 
Prestazioni di assistenza specialistica ambulatoriale. Ministero della 
Salute; 2010.
  49.  Conferenza delle Regioni e delle Province autonome 1O/014/CR10a/C7. 
DRG 206, Tariffa Unica Convenzionale (TUC) per le prestazioni di 
assistenza ospedaliera, regole e tariffe valide per l’anno 2009secondo 
CMS-DRG Versione 24. DRG 206; DRG 202; DRG 199; DRG 480; 
Roma 2010.
  50.  Tumiatti C, Bezzon C, Guasti F, Franchin M. Il costo del trapianto 
d’organo: risultati di uno studio condotto presso l’Azienda Ospedaliera 
di Padova. Azienda Ospedaliera di Padova. 1999:39. valori attualizzati 
al 2009.
  51.  Gazzetta Ufficiale n 216 of 14/09/1996: DM 22/07/1996; 89.7: visita 
specialistica, prima visita. Prestazioni di assistenza specialistica ambu-
latoriale erogabili nell’ambito del Servizio sanitario nazionale e relative 
tariffe.
  52.  Gazzetta Ufficiale n 216 of 14/09/1996: DM 22/07/1996;90.16.3: 
  creatinina, 90.24.3 fosfato organico. Prestazioni di assistenza 
specialistica ambulatoriale erogabili nell’ambito del Servizio sanitario 
nazionale e relative tariffe.
  53.  The National Institute for Health and Clinical Excellence. Social 
value judgements: principles for the development of NICE 
  guidance. Second ed. 2008. http://www.nice.org.uk/media/C18/30/
SVJ2PUBLICATION2008.pdf. Accessed July 14, 2010.
  54.  Buti M, Brosa M, Casado MA, et al. Modeling the cost-effectiveness 
of different oral antiviral therapies in patients with chronic hepatitis B. 
J Hepatol. 2009;51(4):640–646.
  55.  Dakin H, Bentley A, Dusheiko G. Cost-utility analysis of tenofovir 
disoproxil fumarate in the treatment of chronic hepatitis B. Value Health. 
September 3, 2010. [Epub ahead of print].
  56.  Associazione Italiana di Economia Sanitaria (AIES). Proposta 
di linee guida per la valutazione economica degli interventi sani-
tari. PharmacoEconomics – Italian Research Articles. 2009;11: 
83–93.
  57.  Lucioni C, Ravasio R. Come valutare i risultati di uno studio 
  farmacoeconomico?. PharmacoEconomics – Italian Research Articles. 
2004;(3):121–130.
  58.  Messori A, Santarlasci B, Trippoli S, Vaiani M. Controvalore 
  economico del farmaco e beneficio clinico: Stato dell’arte della 
metodologia e   applicazione di un algoritmo farmacoeconomico. 
PharmacoEconomics – Italian Research Articles. 2003;5:53–67.